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a  b  s  t  r  a  c  t
Disseminated infection by Fusarium is a rare, frequently lethal condition in severely
immunocompromised patients, including bone marrow transplant recipients. However,
autologous  bone marrow transplant recipients are not expected to be at high risk to develop
fusariosis.  We  report a rare case of lethal disseminated Fusarium infection in an autologous
bone  marrow transplant recipient during pre-engraftment phase.Keywords:
Stem cell transplant
Autologous
Fusarium
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDA 53-year-old male patient, diagnosed with a grade II fol-
licular  lymphoma, was  submitted to an autologous bone
marrow  transplant (BMT) as therapeutic procedure follow-
ing  recurrence to initial chemotherapy. He had been treated
with  eight cycles of R-CVP (Rituximab, Cyclophosphamide,
Vincristine and prednisone), followed by three cycles of R-
ICE  (Rituximab, Iphosphamide Carboplatin and Etoposide)
and  two cycles of R-DA-EPOCH (dose-adjusted etoposide,
prednisone, vincristine, cyclophosphamide, doxorubicin plus
rituximab).  Conditioning regimen was  prescribed with BEAM
(carmustine,  etoposide, cytosine arabinoside, melphalan).
Prophylactic antimicrobial treatment was  prescribed with ﬂu-
conazole 200 mg  QD. He started with neutropenia in the
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1413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licençaD + 1 post-transplant, and presented fever in the D + 3 post-
transplant, followed by intense myalgia and papular skin
lesion  with rapid dissemination. Some of the papular lesions
progressed with central ischemia and necrosis (Fig. 1). Empiric
antimicrobial treatment with meropenen, vancomycin, and
liposomal  amphotericin 5 mg/kg QD was  initiated. Baseline
total  leukocyte count at the onset of the infectious episode
was  20 leucocytes. A skin biopsy revealed abundant hyphae
structures (Fig. 2). Concomitantly, blood cultures identiﬁed
Fusarium solani through macro- and microculture. The patientão Paulo, Av. Dr. Enéas de Carvalho Aguiar, 470, Cerqueira César,
was  immediately transferred to the intensive care unit, and
voriconazole 400 mg  IV BID was  associated to the antifun-
gal  therapy. Ophthalmologic evaluation revealed no signs of
 de CC BY-NC-ND
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Fig. 1 – Skin papular lesions (A) progressed with central ischemia and necrosis (B).
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sndophthalmitis, and radiographic images were  unremark-
ble.  Laboratory ﬁndings were  heavy myoglobinuria, with
ormal  creatine phosphokinase, worsened renal function
ith  increased blood lactate and elevation of both C-reactive
rotein  and pro-calcitonin. Serum (1-3)--d-glucan was not
ssessed.  Granulocyte was  transfused in two consecutive days
ithout signiﬁcant improvement of the clinical condition.
he  patient developed refractory septic shock and, in spite
f  intensive care support, renal replacement therapy, and
echanical  ventilation, progressed to unresponsive cardiac
rrest  four days after initial clinical presentation. The patient
ad  no previous history of fungal diseases. No skin or nail
esion  had been observed at thorough daily physical examina-
ion  prior to the terminal event. Fungal susceptibility testing
erformed  by E-test method revealed resistance to ﬂuconazole
nd  susceptibility to voriconazole and amphotericin. Investi-
ation  regarding potential source of infection was  conducted,
nd  cultures of tap and shower bath water obtained from the
atient’s  hospital unit were  negative for fungal growth.
ig. 2 – Skin biopsy showing abundant septate hyphae structure
east and hyphae structures in superﬁcial dermis and perivascu
iopsy in 100× Periodic acid-Schiff stain, revealing fungal cell wa
tain, revealing intravascular and epidermal fungal structures, stDiscussion
Fusarium infection is a rare event following autologous BMT,
probably  due to less intense immunossupression relatively
to  allogeneic or cord cell transplant. To our knowledge,
only one case report has described fusariosis in an autol-
ogous  BMT recipient who survived after administration of
amphotericin B, eye enucleation due to fungal endoph-
thalmitis, and neutrophil recovery.1 Other 10 reports of
fusariosis  in an autologous BMT  described fatal outcomes.2,3
Our patient developed a fatal, disseminated fusariosis after
a  very short period of neutropenia. This unexpected out-
come  propelled immediate investigation of the potential
source of fungal contamination. Hospital environmental con-
tamination by fungal specimens has been demonstrated
in medical literature, even in high-efﬁciency particulate air
(HEPA)  ﬁltration-equipped units.4,5 Although cultures of tap
and  shower bath water turned out negative for fungal growth
s. (A) 200× hematoxylin–eosin stain revealing basophilic
lar sites, with minimal inﬂammatory component. (B) Skin
lls in magenta. (C) 200× Grocott’s methenamine silver
ained in black.
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in our case, it is likely that environmental sources, either
hospital-related or not, might be accounted as the infection
source.
A  throughout physical examination, including skin and
nail  inspection did not reveal any lesion that could raise
suspicion for a cutaneous portal of entry, either at hospital
admission or at the post-transplant period. A strong associ-
ation  between invasive Fusarium infection and a superﬁcial
skin  lesion, especially onychomycosis or intertrigo, has been
demonstrated in recent studies.6,7 Moreover, the presence of a
Fusarium skin lesion at admission was  associated with the sub-
sequent development of invasive fusariosis in a prospective
cohort.6
Our patient was  not under prophylactic therapy with
voriconazole, in accordance with his short period of neu-
tropenia  and low risk of invasive mold infection. However,
an  increasing incidence of invasive mold infections has been
reported  among patients with hematological malignancies,8,9
including autologous BMT  recipients.10 In Brazil, cases of
invasive  fusariosis affecting patients with hematologic malig-
nancies  and hematopoietic cell transplant recipients have
been  reported to increase over the years 2000–2010.7 The
widespread use of monoclonal antibodies, including Ritux-
imab,  might potentially increase risk for infections among
hematologic patients,11 but the association with invasive
molds needs further investigation.
Treatment of Fusarium infection is a challenging issue, par-
ticularly  in the immunocompromised host. Lipid formulations
of  amphotericin B and voriconazole are the most frequently
used  medications for ﬁrst-line monotherapy.12 Fusarium sus-
ceptibility  to voriconazole is variable,13 and a breakthrough
infection has been reported in 16 out of 44 consecutive fusario-
sis  cases in a large retrospective report. Among those patients
diagnosed  with fusariosis, 69% were receiving prophylaxis
with  an extended spectrum triazole, either voriconazole (8/16;
50%)  or posaconazole (3/16; 19%).14
Combination therapy with amphotericin formulations,
voriconazole, itraconazole, and echinocandins have been pre-
viously reported,12,15,16 but more  studies are required to
explore the real beneﬁt of this approach.
Granulocyte transfusion is often considered as a sup-
porting therapy for patients with prolonged neutropenia or
abnormal  leukocyte function and severe infection. Although
its  efﬁcacy is not well established, some authors suggest a
beneﬁcial  effect, based on uncontrolled case reports and case
series.17,18
In conclusion, our report illustrates a rare case of a
lethal, disseminated Fusarium infection in an autologous BMT
recipient  during pre-engraftment phase. This unexpected
manifestation reinforces the need for careful clinical eval-
uation  of BMT  candidates, as well as exhaustive vigilance
of  environmental cleansing procedures. Antifungal prophy-
laxis  must be selected according to the characteristics of each
patient,  and further studies assessing the use of antifungal
prophylaxis with activity against molds are necessary.Conﬂicts  of  interest
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